𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer

✍ Scribed by Ji-Youn Han; Kun Young Lim; Sun Young Yu; Tak Yun; Heung Tae Kim; Jin Soo Lee

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
254 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of irinotecan, cisplatin
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
✍ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 87 KB

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Phase II trial of irinotecan and cisplat
Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
✍ Joo Hyuk Sohn; Yong Wha Moon; Chang Geol Lee; Gwi Eon Kim; Kyung Young Chung; Jo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited‐disease small‐cell lung cancer (LD‐SCLC) to evaluate the efficacy and toxicity. ## METHODS. For untreated LD‐SCLC patients, irinotecan (60 mg/m^2^, Days 1, 8,